The Impact of Circulating IGF-1 and IGFBP-2 on Cardiovascular Prognosis in Patients with Acute Coronary Syndrome

Overview

Journal Front Cardiovasc Med

Specialty Cardiology & Vascular Diseases

Date 2023 Mar 27

PMID 36970368

Authors

Wei Wang

Kang Yu

Shou-Yong Zhao

De-Gang Mo

Jia-Hui Liu

Li-Jinn Han

Tai Li

Heng-Chen Yao

Affiliations

Soon will be listed here.

Abstract

Background: While insulin-like growth factor 1 (IGF-1) exerts a cardioprotective effect in the setting of atherosclerosis, insulin-like growth factor binding protein 2 (IGFBP-2) is involved in metabolic syndrome. Although IGF-1 and IGFBP-2 are known to be predictors for mortality in patients with heart failure, their use in clinic as prognostic biomarkers for acute coronary syndrome (ACS) requires investigation. We evaluated the relationship between IGF-1 and IGFBP-2 levels at admission and the risk of major adverse cardiovascular events (MACEs) in patients with ACS.

Methods: A total of 277 ACS patients and 42 healthy controls were included in this prospective cohort study. Plasma samples were obtained and analyzed at admission. Patients were followed for MACEs after hospitalization.

Results: Among patients who suffered acute myocardial infarction, plasma levels of IGF-1 and IGFBP-2 were lower and higher, respectively, as compared to healthy controls (both < 0.05). The mean follow-up period was 5.22 (1.0-6.0) months and MACEs incidence was 22.4% (62 of 277 patients). Kaplan-Meier survival analysis revealed that patients with low IGFBP-2 levels had a greater event-free survival rate than patients with high IGFBP-2 levels ( < 0.001). Multivariate Cox proportional hazards analysis revealed IGFBP-2, but not IGF-1, to be a positive predictor of MACEs (hazard ratio 2.412, 95% CI 1.360-4.277; = 0.003).

Conclusion: Our findings suggest that high IGFBP-2 levels are associated with the development of MACEs following ACS. Moreover, IGFBP-2 is likely an independent predictive marker of clinical outcomes in ACS.

Citing Articles

Identification of Disease-Relevant, Sex-Based Proteomic Differences in iPSC-Derived Vascular Smooth Muscle Cells.

Ariyasinghe N, Gupta D, Escopete S, Rai D, Stotland A, Sundararaman N Int J Mol Sci. 2025; 26(1.

PMID: 39796045 PMC: 11719605. DOI: 10.3390/ijms26010187.

Endothelial IGFBP6 suppresses vascular inflammation and atherosclerosis.

Su M, Zhao W, Jiang H, Zhao Y, Liao Z, Liu Z Nat Cardiovasc Res. 2025; 4(2):145-162.

PMID: 39794479 PMC: 11825279. DOI: 10.1038/s44161-024-00591-0.

Plasma biomarkers in patients with age-related sarcopenia: a proteomic exploration and experimental validation.

Lin Q, Li K, Li L, Guan L, Zeng Y, Cai D Aging Clin Exp Res. 2024; 37(1):13.

PMID: 39725826 PMC: 11671435. DOI: 10.1007/s40520-024-02903-7.

IGFBP-2 in Critical Illness: A Prognostic Marker in the Growth Hormone/Insulin-like Growth Factor Axis.

Savvidis C, Kouroglou E, Kallistrou E, Ragia D, Dionysopoulou S, Gavriiloglou G Pathophysiology. 2024; 31(4):621-630.

PMID: 39585162 PMC: 11587456. DOI: 10.3390/pathophysiology31040045.

IGF-1 levels in the general population, heart failure patients, and individuals with acromegaly: differences and projections from meta-analyses-a dual perspective.

Hu Y, Jiang Y, Duan L, Yang S, Tuniyazi S, Zou J Front Cardiovasc Med. 2024; 11:1379257.

PMID: 39544311 PMC: 11560899. DOI: 10.3389/fcvm.2024.1379257.

References

Muessig J, Lichtenauer M, Wernly B, Kelm M, Franz M, Baz L . Insulin like growth factor binding protein 2 (IGFBP-2) for risk prediction in patients with severe aortic stenosis undergoing Transcatheter Aortic Valve Implantation (TAVI). Int J Cardiol. 2018; 277:54-59. DOI: 10.1016/j.ijcard.2018.09.091. View

Prelevic V, Antunovic T, Radunovic D, Gligorovic Barhanovic N, Gledovic B, Bulatovic N . Decreased insulin-like growth factor-1 (IGF-1) concentration correlates with reduced left-ventricle ejection fraction (LVEF) in hemodialysis patients. Int Urol Nephrol. 2020; 52(12):2385-2391. DOI: 10.1007/s11255-020-02595-8. View

Ock S, Ham W, Kang C, Kang H, Lee W, Kim J . IGF-1 protects against angiotensin II-induced cardiac fibrosis by targeting αSMA. Cell Death Dis. 2021; 12(7):688. PMC: 8270920. DOI: 10.1038/s41419-021-03965-5. View

DAssante R, Arcopinto M, Rengo G, Salzano A, Walser M, Gambino G . Myocardial expression of somatotropic axis, adrenergic signalling, and calcium handling genes in heart failure with preserved ejection fraction and heart failure with reduced ejection fraction. ESC Heart Fail. 2021; 8(2):1681-1686. PMC: 8006736. DOI: 10.1002/ehf2.13067. View

Wallander M, Norhammar A, Malmberg K, Ohrvik J, Ryden L, Brismar K . IGF binding protein 1 predicts cardiovascular morbidity and mortality in patients with acute myocardial infarction and type 2 diabetes. Diabetes Care. 2007; 30(9):2343-8. DOI: 10.2337/dc07-0825. View

Lappas M, Jinks D, Shub A, Willcox J, Georgiou H, Permezel M . Postpartum IGF-I and IGFBP-2 levels are prospectively associated with the development of type 2 diabetes in women with previous gestational diabetes mellitus. Diabetes Metab. 2016; 42(6):442-447. DOI: 10.1016/j.diabet.2016.06.004. View

Wheatcroft S, Kearney M, Shah A, Ezzat V, Miell J, Modo M . IGF-binding protein-2 protects against the development of obesity and insulin resistance. Diabetes. 2007; 56(2):285-94. PMC: 4295171. DOI: 10.2337/db06-0436. View

Hassfeld S, Eichhorn C, Stehr K, Naegele H, Geier C, Steeg M . Insulin-like growth factor-binding proteins 2 and 3 are independent predictors of a poor prognosis in patients with dilated cardiomyopathy. Heart. 2007; 93(3):359-60. PMC: 1861437. DOI: 10.1136/hrt.2006.090092. View

Haywood N, A Slater T, Matthews C, Wheatcroft S . The insulin like growth factor and binding protein family: Novel therapeutic targets in obesity & diabetes. Mol Metab. 2018; 19:86-96. PMC: 6323188. DOI: 10.1016/j.molmet.2018.10.008. View

10.

Osterziel K, Blum W, Strohm O, Dietz R . The severity of chronic heart failure due to coronary artery disease predicts the endocrine effects of short-term growth hormone administration. J Clin Endocrinol Metab. 2000; 85(4):1533-9. DOI: 10.1210/jcem.85.4.6575. View

11.

Clemmons D . Role of IGF Binding Proteins in Regulating Metabolism. Trends Endocrinol Metab. 2016; 27(6):375-391. DOI: 10.1016/j.tem.2016.03.019. View

12.

Jonker S, Giraud G, Chang E, Elman M, Louey S . Coronary vascular growth matches IGF-1-stimulated cardiac growth in fetal sheep. FASEB J. 2020; 34(8):10041-10055. PMC: 7688557. DOI: 10.1096/fj.202000215R. View

13.

Bruno C, Silvestrini A, Calarco R, Favuzzi A, Vergani E, Nicolazzi M . Anabolic Hormones Deficiencies in Heart Failure With Preserved Ejection Fraction: Prevalence and Impact on Antioxidants Levels and Myocardial Dysfunction. Front Endocrinol (Lausanne). 2020; 11:281. PMC: 7235369. DOI: 10.3389/fendo.2020.00281. View

14.

Yeves A, Burgos J, Medina A, Villa-Abrille M, Ennis I . Cardioprotective role of IGF-1 in the hypertrophied myocardium of the spontaneously hypertensive rats: A key effect on NHE-1 activity. Acta Physiol (Oxf). 2019; 224(2):e13092. DOI: 10.1111/apha.13092. View

15.

Caplice N, DeVoe M, Choi J, Dahly D, Murphy T, Spitzer E . Randomized placebo controlled trial evaluating the safety and efficacy of single low-dose intracoronary insulin-like growth factor following percutaneous coronary intervention in acute myocardial infarction (RESUS-AMI). Am Heart J. 2018; 200:110-117. DOI: 10.1016/j.ahj.2018.03.018. View

16.

Griffiths M, Yang J, Nies M, Vaidya D, Brandal S, Williams M . Pediatric pulmonary hypertension: insulin-like growth factor-binding protein 2 is a novel marker associated with disease severity and survival. Pediatr Res. 2020; 88(6):850-856. PMC: 7704926. DOI: 10.1038/s41390-020-01113-x. View

17.

Hajsadeghi S, Mohseni H, Moradi M, Rahmani E, Kordshakeri K, Manteghi M . Evaluating the association between insulin-like growth factor-1 values and short-term survival rates following acute myocardial infarction. Clin Med Insights Cardiol. 2011; 5:7-11. PMC: 3041238. DOI: 10.4137/CMC.S6629. View

18.

van den Beld A, Carlson O, Doyle M, Rizopoulos D, Ferrucci L, van der Lely A . IGFBP-2 and aging: a 20-year longitudinal study on IGFBP-2, IGF-I, BMI, insulin sensitivity and mortality in an aging population. Eur J Endocrinol. 2018; 180(2):109-116. PMC: 6445262. DOI: 10.1530/EJE-18-0422. View

19.

De Giorgi A, Marra A, Iacoviello M, Triggiani V, Rengo G, Cacciatore F . Insulin-like growth factor-1 (IGF-1) as predictor of cardiovascular mortality in heart failure patients: data from the T.O.S.CA. registry. Intern Emerg Med. 2022; 17(6):1651-1660. PMC: 9463276. DOI: 10.1007/s11739-022-02980-4. View

20.

Carter S, Li Z, Lemieux I, Almeras N, Tremblay A, Bergeron J . Circulating IGFBP-2 levels are incrementally linked to correlates of the metabolic syndrome and independently associated with VLDL triglycerides. Atherosclerosis. 2014; 237(2):645-51. DOI: 10.1016/j.atherosclerosis.2014.09.022. View